Free Trial Information
BioCentury | Jun 13, 2019
Company News

June 12 Company Quick Takes: Macao approves Zai's Zejula; plus Roche, NIH, CVS and Dassault-Medidata

Zai obtains Zejula's approval in Macao Zai Lab Ltd. (NASDAQ:ZLAB) said it has received approval in Macao to market PARP inhibitor Zejula niraparib to treat ovarian cancer. Zai holds its local rights from the Tesaro...
Read More
BioCentury | Apr 5, 2010
Company News

Aureus other news

...Aureus joined the Biointelligence R&D program, a project coordinated by software company Dassault Systemes (Velizy-Villacoublay, France) that...
...Paris, France Aureus joined the Biointelligence R&D program, a project coordinated by software company Dassault Systemes...
Read More
Items per page:
1 - 2 of 2
BioCentury | Jun 13, 2019
Company News

June 12 Company Quick Takes: Macao approves Zai's Zejula; plus Roche, NIH, CVS and Dassault-Medidata

Zai obtains Zejula's approval in Macao Zai Lab Ltd. (NASDAQ:ZLAB) said it has received approval in Macao to market PARP inhibitor Zejula niraparib to treat ovarian cancer. Zai holds its local rights from the Tesaro...
Read More
BioCentury | Apr 5, 2010
Company News

Aureus other news

...Aureus joined the Biointelligence R&D program, a project coordinated by software company Dassault Systemes (Velizy-Villacoublay, France) that...
...Paris, France Aureus joined the Biointelligence R&D program, a project coordinated by software company Dassault Systemes...
Read More
Items per page:
1 - 2 of 2